Article
Biochemistry & Molecular Biology
Valerija Begic, Petra Korac, Slavko Gasparov, Marija Rozman, Petra Simicic, Snjezana Zidovec-Lepej
Summary: This study investigated the distribution of EBV genotypes 1 and 2, as well as LMP1 gene variants, in Hodgkin lymphoma patients. The results showed that EBV genotype 1 was exclusively present in all classical HL samples. Furthermore, the wild-type strain B95-8 and the Mediterranean subtype with a 30 bp deletion were found to be predominant in the distribution of EBV LMP1 variants. These findings contribute to our understanding of EBV immunobiology in cHL and have implications for the development of prophylactic and therapeutic vaccines.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Geok Wee Tan, Peijia Jiang, Ilja M. Nolte, Kushi Kushekhar, Rianne N. Veenstra, Bouke G. Hepkema, Ruth F. Jarrett, Anke van den Berg, Arjan Diepstra
Summary: This study found that loss and retention of HLA expression is associated with presence of known susceptibility HLA alleles, suggesting that HLA associations in cHL are related to peptide binding capacities of specific HLA alleles. Several HLA alleles are strongly linked to cHL susceptibility, even in subgroups stratified by EBV presence.
Article
Cell Biology
Elena Gerhard-Hartmann, Korinna Joehrens, Lisa-Marie Schinagl, Alberto Zamo, Andreas Rosenwald, Ioannis Anagnostopoulos, Mathias Rosenfeldt
Summary: This study investigates the Epstein-Barr virus (EBV) latency types in 19 cases of EBV-positive nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) and finds that the majority of cases have EBV latency type II, which is associated with missing CD30 expression. The study suggests that factors such as the presence of Hodgkin and Reed-Sternberg (HRS) cells, frequent CD30 expression, and preservation of the B-cell transcription programme contribute to the distinction from classic Hodgkin lymphoma.
Article
Immunology
Peijia Jiang, Ilja M. Nolte, Bouke G. Hepkema, Marijke Stulp, Anke van den Berg, Arjan Diepstra
Summary: The study found significant differences in KIR types between EBV+ and EBV- classic Hodgkin lymphoma patients, especially in nodular sclerosis cHL. The frequency of KIR haplotype B subgroup was significantly lower in EBV+ nodular sclerosis cHL patients, which may result in a more efficient control over EBV-infected B cells. The study suggests that carriers of the KIR haplotype B subgroup are less likely to develop EBV+ nodular sclerosis cHL.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Medicine, General & Internal
Pauline Brice, Eric de Kerviler, Jonathan W. Friedberg
Summary: Classical Hodgkin lymphoma is a relatively common lymphoma that is generally considered highly curable with standard first-line chemotherapy and radiotherapy, although some patients may not be cured or may experience late toxic effects leading to premature death. Recent changes in the gold standard of chemotherapy, now often including immunotherapy in relapse settings, have further impacted treatment outcomes.
Article
Pathology
Christopher Batuello, Emily F. Mason
Summary: CD200 expression can differentiate EBV+ LBCL from CHL, with negative or partial/weak staining favoring a diagnosis of EBV+ LBCL and strong diffuse staining favoring a diagnosis of CHL.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY
(2023)
Article
Multidisciplinary Sciences
Tsvetelina Kostadinova Popova, Liliya Ivanova Ivanova, Ivaylo Georgiev Hristov, Zhivka Stoykova, Tatina Todorova Todorova, Merlin Erol Efraim, Liana Todorova Gercheva
Summary: This study assessed the presence of plasma EBV DNA in Bulgarian patients with Hodgkin lymphoma using Real-time PCR testing and found detectable levels in 40.7% of the patients. The results suggest that determination of EBV-DNA is important for diagnosis and monitoring of EBV-associated HL cases.
COMPTES RENDUS DE L ACADEMIE BULGARE DES SCIENCES
(2021)
Article
Oncology
Jia-Qi Qin, Hua Yin, Jia-Zhu Wu, Rui-Ze Chen, Yi Xia, Li Wang, Hua-Yuan Zhu, Lei Fan, Jian-Yong Li, Jin-Hua Liang, Wei Xu
Summary: This study found that pretreatment EBV DNA positivity in HL patients is associated with inferior PFS and OS. Monitoring changes in EBV DNA copies can be used to reflect treatment response, risk of disease relapse, and prognosis in HL patients.
Editorial Material
Hematology
Lucy C. Fox
Summary: In this study, Flerlage et al performed whole genome sequencing on individuals with and without Hodgkin lymphoma (HL) in families with a family history of the disease. They identified risk variants for HL and provided a starting point for further investigation of these variants in other HL patients and their families.
Editorial Material
Hematology
Graham P. Collins
Summary: In this study, combining the histone deacetylase inhibitor vorinostat with the programmed cell death protein-1 inhibitor pembrolizumab resulted in a remarkable response rate, even in patients refractory to prior PD1i therapy.
Review
Biochemistry & Molecular Biology
Fabrice Jardin
Summary: The tumor cells in classical Hodgkin lymphoma (cHL) have unique features, such as their rarity compared to the reactive microenvironment, the loss of B-cell phenotype markers, immune escape capacity, and activation of key biological pathways. Targeting these pathways remains a challenging but potentially impactful therapeutic strategy.
Article
Hematology
Dennis A. Eichenauer, Horst Muller, Leonard Elger, Helen Goergen, Michael Fuchs, Stefanie Kreissl, Boris Boll, Volker Diehl, Bastian von Tresckow, Peter Borchmann, Andreas Engert
Summary: NHL after cHL is a rare event that primarily affects older individuals, with a five-year event-free survival and overall survival estimates of 36.9% and 44.2% respectively.
BRITISH JOURNAL OF HAEMATOLOGY
(2021)
Article
Infectious Diseases
Rana Habeeb, Lina al Hafar, Fawza Monem
Summary: This study confirmed that plasma EBV DNA can serve as a noninvasive biomarker for the diagnosis of EBV-positive Hodgkin lymphoma, and revealed a high EBV DNA load in these patients, indicating poor prognosis.
JOURNAL OF INFECTION IN DEVELOPING COUNTRIES
(2021)
Review
Oncology
Marc A. Weniger, Ralf Kuppers
Summary: Classical Hodgkin lymphoma (cHL) has unique biological features such as the orchestration of a complex microenvironment by HRS cells, the major role of Epstein-Barr virus in lymphomagenesis, and the defining interplay of genetic lesions and cellular origin. These factors contribute to the constitutive activation of multiple signaling pathways in cHL.
Review
Medicine, General & Internal
Giuseppina Opinto, Claudio Agostinelli, Sabino Ciavarella, Attilio Guarini, Eugenio Maiorano, Giuseppe Ingravallo
Summary: Classical Hodgkin's lymphoma is a particular lymphoma characterized by few tumor cells surrounded by an inflammatory microenvironment. The tumor cells reprogram and evade antitumor mechanisms of normal cells, while the microenvironment cells are essential for the growth and survival of the tumor cells. Recent advances in gene expression profiling analysis have been applied to study the microenvironment component in cHL, and therapies targeting both neoplastic cells and the cellular components of the background have been described.
JOURNAL OF CLINICAL MEDICINE
(2021)